MedDataX Logo

Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal

NCT01404000 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-11-15

No results posted yet for this study

Summary

The purpose of this study s to determine whether treatment with Iodinated Active Charcoal can improve lung function and physical capacity in patients with chronic obstructive lung disorders. The rational for the study is the observation that COPD patients have an increased tissue load of mercury interfering with the function by NeuroEpithelial Endocrine (NEE) cells in the respiratory tract. Mercury binding to these NEE cells leads to an increased smooth muscle tonus and a reduced response to bronchodilator treatment. Initial observational data have shown an improved lung function and improved functional capacity after treatment motivating a larger placebo controlled POC study

Conditions

  • Chronic Obstructive Lung Disease

Interventions

DRUG

Iodinated Active Charcoal (IodoCarb)

3 g will be given as an oral suspension once daily for 56 days

Sponsors & Collaborators

  • PharmaLundensis AB

    lead INDUSTRY

Principal Investigators

  • Leif Bjermer, MD Professor · Dept of Respiratory Medicine & Allergology, Skane UNiversity Hospital, Lund, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • Sweden

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01404000 on ClinicalTrials.gov